approxim
million
adult
unit
state
account
million
physician
visit
million
hospit
death
per
year
mani
cap
patient
requir
hospit
admiss
due
diseas
sever
decompens
underli
comorbid
diseas
social
reason
sever
pneumonia
requir
critic
care
morbid
mortal
patient
sever
cap
remain
high
despit
advanc
antimicrobi
therapi
critic
care
admit
icu
patient
requir
mechan
ventil
time
admiss
present
concomit
septic
shock
mortal
rate
high
rang
epidemiolog
although
definit
sever
pneumonia
remain
somewhat
subject
imprecis
de
facto
respiratori
andor
circulatori
failur
often
defin
entiti
variou
cap
score
system
devis
valid
attempt
aid
clinician
regard
treatment
prognosi
site
care
although
score
system
sensibl
reflect
diseas
sever
continu
present
challeng
inadequaci
differ
method
deriv
includ
differ
intens
care
unit
icu
refer
popul
admiss
criteria
confound
variabl
treatment
restrict
limit
elderli
model
variabl
includ
variat
time
cours
pneumonia
sever
result
inconsist
perform
tool
wide
cite
definit
sever
cap
howev
one
use
present
joint
guidelin
infecti
diseas
societi
america
idsa
american
thorac
societi
at
box
major
criteria
sever
cap
includ
either
concomit
septic
shock
need
mechan
ventil
minor
criteria
includ
follow
respiratori
rate
greater
equal
breath
min
pao
fio
ratio
less
equal
multilobar
infiltr
blood
urea
nitrogen
greater
equal
mgdl
leukopenia
white
blood
cell
wbc
count
cellsmm
thrombocytopenia
platelet
count
cellsmm
hypothermia
core
temperatur
c
hypotens
requir
aggress
fluid
resuscit
characterist
also
suggest
idsaat
icu
admiss
criteria
cours
patient
meet
criteria
admit
icu
decis
may
depend
numer
factor
includ
local
polici
patient
wish
resourc
avail
includ
avail
intermedi
care
unit
exampl
hospit
rate
influenza
pneumonia
among
adult
older
year
vari
consider
geograph
region
canada
data
canadian
institut
health
inform
demonstr
rate
highest
northwest
territori
per
compar
lowest
rate
quebec
per
overal
nation
averag
per
addit
rate
cap
vari
season
case
occur
winter
month
influenza
infect
preval
rate
pneumonia
higher
men
women
black
compar
caucasian
presum
relat
variou
genet
polymorph
andor
socioeconom
factor
well
understood
lastli
cap
incid
increas
significantli
age
due
immunosenesc
given
age
popul
expect
steadili
increas
next
decad
prospect
studi
adult
pneumonia
present
emerg
depart
hospit
edmonton
canada
admit
icu
much
higher
percentag
younger
patient
admit
icu
compar
older
patient
exampl
admit
icu
year
age
percentag
markedli
declin
investig
role
infect
parturi
cat
transmiss
coxiella
burnetii
maritim
canada
found
incub
period
day
shorter
incub
period
associ
exposur
product
concept
indic
doserespons
effect
similarli
albrich
colleagu
demonstr
adult
south
africa
affect
human
immunodefici
viru
hiv
microorgan
load
associ
develop
pneumonia
specif
equal
copiesml
lyta
gene
detect
realtim
polymeras
chain
reaction
pcr
greater
equal
cfuml
streptococcu
pneumonia
quantit
cultur
nasopharyng
swab
associ
develop
pneumococc
pneumonia
werno
colleagu
likewis
found
patient
pneumonia
bacteri
load
measur
quantit
lyta
pcr
sputum
serum
urin
show
increas
sever
pneumonia
increas
bacteri
load
associ
high
bacteri
load
subsequ
develop
septic
shock
patient
communityacquir
pneumonia
also
describ
abbrevi
bun
blood
urea
nitrogen
fio
fraction
inspir
oxygen
pao
arteri
partial
pressur
oxygen
criteria
consid
includ
hypoglycemia
nondiabet
patient
acut
alcohol
alcohol
withdraw
hyponatremia
unexplain
metabol
acidosi
elev
lactat
level
cirrhosi
asplenia
b
need
invas
ventil
substitut
respiratori
rate
greater
equal
breathsmin
pao
fio
less
equal
c
result
infect
alon
usa
strain
methicillinresist
staphylococcu
aureu
exemplifi
concept
increas
virul
sever
virul
gene
includ
lukspv
lukfpv
arca
code
patonvalentin
leukocidin
arginin
catabol
mobil
element
respect
strain
success
spread
unit
state
countri
contin
strain
often
caus
sever
necrot
pneumonia
recent
public
describ
patient
methicillinsensit
aureu
cap
due
pantonvalentin
leukocidin
secret
strain
illustr
lethal
infect
affect
mainli
healthi
children
young
adult
thirteen
patient
die
multilobar
pneumonia
requir
mechan
ventil
mean
age
die
year
year
case
pseudomona
aeruginosa
caus
pneumonia
otherwis
healthi
young
adult
mortal
rate
associ
exposur
aerosol
contamin
water
one
studi
isol
patient
virul
mous
model
p
aeruginosa
isol
legionnair
diseas
consid
young
adult
sever
pneumonia
outbreak
gave
diseas
name
led
isol
caus
microorgan
associ
annual
convent
american
legion
held
philadelphia
juli
one
hundr
eightytwo
attende
develop
pneumonia
one
hundr
fortyseven
hospit
die
evolutionari
strategi
allow
legionella
surviv
amoeba
allow
surviv
human
alveolar
macrophag
instanc
case
hantaviru
target
cell
infect
may
result
sever
pneumonia
hantaviru
infect
endotheli
cell
via
nonlyt
mechan
disrupt
endotheli
integr
result
low
pressur
pulmonari
edema
manifest
sever
pneumonia
lastli
sever
acut
respiratori
syndrom
sar
coronaviru
coronaviru
respons
sar
caus
case
pneumonia
start
novemb
result
death
agent
caus
sever
pneumonia
otherwis
healthi
individu
well
other
bat
viru
use
angiotensinconvert
enzym
receptor
enter
host
cell
trigger
massiv
enzymat
cleavag
result
sever
physiolog
derang
manifest
sever
pneumonia
addit
bacteri
burden
virul
may
subtl
impair
immun
respons
contribut
sever
pneumonia
exampl
low
concentr
immunoglobulin
g
igg
found
patient
noninfluenza
sever
cap
low
concentr
found
pneumonia
due
influenza
viru
mannosebind
lectin
function
lower
legionnair
diseas
agematch
sexmatch
uninfect
control
homozygos
receptor
predispos
sever
bacterem
pneumococc
pneumonia
leukocyt
receptor
fc
portion
igg
play
key
role
respons
pathogen
pneumonia
mediat
phagocytosi
respiratori
burst
cytokin
product
antigen
present
regul
antibodi
respons
spring
novel
influenza
viru
swine
origin
caus
human
infect
result
estim
million
ill
sligl
marri
hospit
death
unit
state
midfebruari
although
overal
case
fatal
rate
low
approxim
hospit
patient
admit
icu
patient
die
although
pregnant
women
repres
popul
among
patient
viru
infect
account
hospit
patient
icu
patient
patient
die
interferon
induc
transmembran
protein
famili
member
ifitm
play
role
restrict
replic
multipl
pathogen
virus
patient
hospit
pandem
influenza
like
minor
allel
alter
splice
acceptor
site
result
reduc
abil
restrict
influenza
vitro
exampl
illustr
sever
pneumonia
otherwis
healthi
person
like
due
combin
pathogen
doseburden
virul
well
subtl
impair
host
defens
despit
constant
exposur
particul
materi
microorgan
via
microaspir
lower
respiratori
tract
remain
steril
innat
acquir
pulmonari
defens
mechan
develop
cap
indic
defect
host
defens
exposur
particularli
virul
microorgan
overwhelm
inoculum
microorgnan
combin
factor
previous
discuss
variou
virul
factor
enabl
microflora
establish
infect
exampl
chlamydophila
pneumonia
produc
ciliostat
factor
mycoplasma
pneumonia
shear
respiratori
cilia
influenza
virus
reduc
tracheal
mucou
veloc
pneumonia
polysaccharid
capsul
inhibit
phagocytosi
microorgan
innat
resist
immun
defens
exampl
mycobacteri
speci
nocardia
legionella
resist
microbicid
activ
phagocyt
addit
pathogen
characterist
host
characterist
import
predict
risk
infect
box
sever
predispos
host
condit
describ
cap
includ
alter
level
conscious
tobacco
smoke
alcohol
consumpt
hypoxemia
acidosi
toxic
inhal
pulmonari
edema
uremia
malnutrit
immun
suppress
result
solid
organ
hematopoiet
stem
cell
transplant
chemotherapi
chronic
glucocorticoid
use
biolog
therapi
infect
hiv
advanc
age
structur
lung
diseas
cystic
fibrosi
bronchiectasi
chronic
obstruct
pulmonari
diseas
copd
previou
pneumonia
chronic
bronchiti
ciliari
dysfunct
immotil
cilia
syndrom
kartagen
syndrom
young
syndrom
also
known
sinusitisinfertil
syndrom
barryperkinsyoung
syndrom
rare
condit
present
bronchiectasi
rhinosinus
infertil
due
abnorm
viscou
mucu
dysphagia
viral
respiratori
infect
lung
malign
bronchial
obstruct
due
stenosi
tumor
foreign
bodi
increas
incid
cap
due
increas
gastric
ph
well
document
ubiquit
use
blocker
proton
pump
inhibitor
antacid
medic
antipsychot
inhal
glucocorticoid
associ
increas
risk
cap
hundr
microorgan
includ
bacteria
virus
fungi
parasit
caus
cap
howev
case
pneumonia
caus
hand
pathogen
vari
distribut
geographi
clinic
set
caus
bacteri
cap
tradit
classifi
group
typic
atyp
pathogen
typic
microorgan
includ
pneumonia
haemophilu
influenza
group
streptococcu
moraxella
catarrhali
staphylococcu
aureu
anaerob
aerob
gramneg
enter
bacilli
atyp
pathogen
includ
legionella
spp
mycoplasma
pneumonia
chlamydophila
formerli
chlamydia
pneumonia
chlamydophila
psittaci
specif
find
histori
physic
examin
routin
laboratoryimag
test
allow
clinician
distinguish
typic
atyp
pathogen
common
pathogen
patient
sever
cap
box
includ
pneumonia
haemophilu
influenza
staphylococcu
aureu
gramneg
enter
bacilli
occasion
p
aeruginosa
pneumonia
frequent
isol
pathogen
wherea
aureu
gramneg
enter
p
aeruginosa
tend
associ
specif
patient
subtyp
exampl
aureu
pneumonia
common
follow
influenza
infect
wherea
p
aeruginosa
infect
preval
patient
previous
expos
antimicrobi
structur
lung
diseas
cystic
fibrosi
bronchiectasi
chronic
treat
corticosteroid
mgd
prednison
equival
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
speci
less
commonli
isol
patient
sever
cap
howev
may
reflect
lack
rapid
specif
standard
test
detect
frequenc
legionella
well
less
common
caus
mycobacterium
tuberculosi
coxiella
burnetii
q
fever
francisella
tularensi
tularemia
endem
fungi
histoplasma
coccidioid
blastomyc
vari
epidemiolog
exposur
respiratori
viru
infect
particular
influenza
result
sever
pneumon
without
secondari
bacteri
pneumonia
despit
routin
microbiolog
test
patient
sever
cap
microbi
diagnosi
confirm
half
patient
best
drugresist
pneumonia
penicillin
resist
pneumonia
first
describ
south
africa
sinc
resist
pneumococci
varieti
antimicrobi
agent
includ
betalactam
macrolid
tetracyclin
folat
inhibitor
fluoroquinolon
evolv
worldwid
rate
penicillin
resist
vari
geograph
region
higher
rate
asiapacif
region
compar
unit
state
canada
understand
impact
penicillin
resist
pneumonia
outcom
complic
recent
chang
suscept
breakpoint
penicillin
minimum
inhibitori
concentr
mic
breakpoint
increas
substanti
nonmening
pneumococc
infect
place
much
fewer
organ
intermedi
resist
categori
chang
disproportion
high
number
clinic
isol
consid
penicillin
intermedi
resist
current
definit
howev
approxim
pneumococci
fulli
suscept
penicillin
earlier
studi
unabl
demonstr
associ
betalactam
resist
poor
outcom
instead
suggest
factor
age
underli
diseas
sever
ill
greater
predictor
mortal
macrolid
resist
also
becom
increasingli
preval
worldwid
isol
demonstr
resist
unit
state
abbrevi
hmpv
human
metapneumoviru
rsv
respiratori
syncyti
viru
select
popul
patient
previous
expos
antimicrobi
structur
lung
diseas
treat
chronic
corticosteroid
resist
unit
state
howev
lowlevel
effluxmedi
vs
resist
due
alter
ribosom
target
site
seen
commonli
europ
associ
poor
outcom
respiratori
fluoroquinolon
resist
remain
low
surveil
studi
suggest
less
resist
north
america
major
risk
factor
acquisit
resist
recent
antibiot
exposur
prompt
recommend
avoid
agent
prescrib
prior
month
possibl
methicillinresist
staphylococcu
aureu
mrsa
first
describ
sinc
spread
worldwid
mrsa
common
caus
nosocomi
communityacquir
infect
preval
methicillinresist
among
aureu
isol
vari
patient
popul
geographi
health
care
set
high
preval
icu
unit
state
methicillinresist
mediat
penicillinbind
protein
pbp
alter
bind
protein
encod
meca
gene
meca
gene
locat
mobil
genet
element
call
staphylococc
chromosom
cassett
sccmec
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
recent
emerg
caus
sever
necrot
cap
although
gener
virul
compar
hospitalacquir
hamrsa
strain
camrsa
tend
suscept
nonbetalactam
antibiot
clindamycin
tetracyclin
trimethoprimsulfamethoxazol
result
shorter
sccmec
mobil
element
type
iv
v
less
abl
carri
addit
resist
gene
specif
camrsa
strain
eg
associ
product
pantonvalentin
leukocidin
pvl
toxin
lyse
neutrophil
often
result
necrot
pneumonia
lung
abscess
empyema
variou
report
strain
caus
sever
rapidli
progress
necrot
pneumonia
mainli
otherwis
healthi
children
young
adult
high
associ
mortal
well
document
systemat
review
patient
estim
incid
mrsa
cap
case
per
seventyf
patient
younger
year
influenzalik
symptom
present
patient
major
multilobar
consolid
bilater
lung
infiltr
patient
requir
icu
care
prolong
day
length
stay
high
mortal
risk
factor
camrsa
includ
skin
trauma
contact
sport
particip
inject
drug
use
men
sex
men
crowd
live
condit
recent
incarcer
priorknown
mrsa
colon
camrsa
pneumonia
also
suspect
young
otherwis
healthi
patient
histori
influenzalik
ill
present
sever
pneumonia
season
influenza
occur
almost
exclus
winter
month
result
major
morbid
mortal
cost
fact
season
influenza
estim
result
million
hospit
day
million
outpati
visit
billion
medic
cost
annual
unit
state
patient
admit
hospit
influenza
infect
mainli
elderli
sever
comorbid
diseas
requir
icu
admiss
addit
major
impact
caus
season
influenza
threat
pandem
influenza
everpres
recent
influenza
pandem
serv
remind
us
loom
danger
genet
reassort
viru
swine
avian
human
first
identifi
march
spread
southwestern
unit
state
mexico
worldwid
result
death
young
patient
disproport
affect
presum
due
crossimmun
elderli
patient
exposur
similar
influenza
strain
circul
studi
use
mathemat
model
approxim
impact
pandem
diseas
center
diseas
control
prevent
estim
fatal
case
occur
unit
state
april
april
australia
approxim
popul
develop
ill
infect
patient
hospit
disproportion
percentag
hospit
patient
requir
icu
care
among
critic
ill
canadian
patient
mean
age
low
year
common
preexist
comorbid
chronic
lung
diseas
obes
aborigin
canadian
overrepres
patient
develop
diffus
rapidli
progress
bilater
pneumon
requir
mechan
ventil
secondari
bacteri
pneumonia
diagnos
case
commonli
due
aureu
pneumonia
overal
mortal
high
day
highli
pathogen
avian
influenza
virus
endem
among
bird
poultri
popul
asian
countri
first
report
clinic
diseas
human
hong
kong
case
occur
poultri
outbreak
livebird
market
outbreak
associ
high
mortal
high
incid
pneumonia
half
case
requir
intens
care
treatment
although
sporad
transmiss
avian
influenza
virus
human
document
emerg
pandem
strain
possibl
addit
influenza
respiratori
virus
potenti
epidem
spread
sar
outbreak
good
exampl
begin
februari
approxim
case
sever
rapidli
progress
respiratori
diseas
report
guangdong
provinc
china
novel
sar
coronaviru
subsequ
spread
worldwid
larg
number
case
report
hong
kong
vietnam
singapor
canada
total
case
death
casefat
rate
morbid
mortal
epidem
signific
patient
affect
sar
requir
critic
care
sever
hypoxia
acut
respiratori
distress
syndrom
ard
novel
beta
coronaviru
caus
diseas
nine
patient
associ
high
mortal
report
although
sar
longer
threat
pathogen
remain
threat
await
chanc
sun
diagnosi
cap
defin
acut
infect
lung
parenchyma
acquir
commun
ie
patient
hospit
resid
longterm
care
facil
week
symptom
onset
cap
distinguish
subtyp
pneumonia
includ
hospitalacquir
pneumonia
health
care
associ
pneumonia
import
epidemiolog
subtyp
differ
microbiolog
empir
therapi
outcom
diagnost
approach
sever
cap
includ
clinic
criteria
radiograph
evalu
diagnost
test
microbi
caus
common
clinic
symptom
sever
cap
includ
cough
fever
dyspnea
pleurit
chest
pain
sputum
product
purul
sputum
product
common
bacteri
pneumonia
specif
descript
sputum
sever
communityacquir
pneumonia
color
consist
eg
rustcolor
sputum
pneumonia
red
current
jelli
sputum
klebsiella
infect
prove
help
distinguish
microbi
caus
patient
may
also
present
mental
statu
chang
gastrointestin
symptom
nausea
vomit
diarrhea
physic
examin
sign
commonli
includ
fever
although
less
reliabl
elderli
patient
tachypnea
tachycardia
patient
overwhelm
sepsi
underli
comorbid
diseas
endstag
liver
diseas
malnutrit
may
present
hypothermia
instead
fever
bronchial
breath
sound
egophoni
may
present
auscult
howev
individu
combin
clinic
find
found
accur
predict
whether
patient
pneumonia
sever
cap
patient
sever
hypoxia
pao
mm
hg
despit
supplement
oxygen
hypercapnia
paco
rise
mm
hg
respiratori
acidosi
gener
requir
intub
mechan
ventil
although
object
measur
suggest
decis
initi
mechan
ventil
base
global
clinic
assess
patient
cap
septic
shock
present
hypotens
systol
blood
pressur
mm
hg
unrespons
fluid
resuscit
requir
vasopressor
support
laboratori
investig
leukocytosi
common
left
shift
immatur
cell
leukopenia
also
occur
particular
critic
ill
patient
overwhelm
sepsi
patient
commonli
present
concomit
multiorgan
dysfunct
acut
kidney
injuri
aki
hepat
dysfunct
dissemin
intravascular
coagul
lactic
acidosi
encephalopathi
creactiv
protein
crp
procalcitonin
pct
use
vari
success
help
distinguish
bacteri
nonbacteri
pneumonia
crp
acutephas
reactant
produc
predominantli
hepatocyt
respons
cytokin
tumor
necrosi
factor
neither
sensit
specif
infect
howev
markedli
elev
crp
level
strongli
associ
infect
infect
found
approxim
patient
level
greater
mgl
patient
valu
greater
mgl
studi
crp
level
greater
mgl
associ
sensit
specif
bacteri
pneumonia
crp
may
also
elev
patient
viral
infect
although
often
extent
bacteri
infect
addit
crp
level
may
correl
diseas
sever
studi
cap
patient
demonstr
median
crp
level
higher
hospit
patient
compar
ambulatori
patient
data
crp
test
exclus
patient
sever
cap
lack
given
poor
specif
hospit
patient
use
crp
test
adjunct
diagnosi
bacteri
infect
remain
minim
benefit
pct
precursor
calcitonin
releas
respons
microbi
toxin
lipopolysaccharid
gramneg
infect
host
inflammatori
mediat
tumor
necrosi
factor
result
high
serum
level
activ
bacteri
infect
pct
appear
sensit
crp
detect
bacteri
pneumonia
previou
studi
suggest
pct
level
less
mcgl
discourag
use
antibacteri
therapi
wherea
level
greater
mcgl
suggest
therapi
studi
demonstr
lower
rate
antibiot
exposur
pct
test
use
addit
level
correl
diseas
sever
mortal
bacteremia
clinic
measur
pct
may
help
distinguish
bacteri
viral
pneumonia
predict
sever
outcom
reduc
antimicrobi
use
discontinu
strategi
base
pct
test
led
reduct
durat
therapi
increas
antibioticfre
day
without
neg
affect
outcom
presenc
opac
plain
chest
radiographi
gold
standard
radiograph
diagnosi
pneumonia
plain
film
wide
avail
virtual
hospit
set
minim
invas
inexpens
obtain
critic
ill
patient
suspect
pneumonia
radiograph
find
cap
includ
lobar
multilobar
consolid
fig
interstiti
infiltr
cavit
posteroanterior
later
radiograph
prefer
rare
possibl
critic
ill
patient
portabl
anteroposterior
ap
film
therefor
commonli
obtain
undoubtedli
lower
qualiti
given
suboptim
qualiti
portabl
ap
film
well
substanti
differ
individu
interpret
plain
radiograph
among
emerg
physician
intensivist
even
radiologist
comput
tomographi
ct
scan
commonli
pursu
critic
ill
patient
fig
particular
specif
diseas
complic
empyema
lung
abscess
suspect
level
radiat
exposur
ct
scan
vari
due
technic
factor
gener
high
success
reduc
radiat
dose
maintain
diagnost
accuraci
import
specif
pediatr
popul
given
low
likelihood
identif
microbi
pathogen
patient
sever
cap
treat
empir
despit
effort
increas
pathogen
detect
via
appropri
test
use
pathogendirect
therapi
associ
substanti
benefit
includ
avoid
unnecessari
advers
event
reduct
antimicrobi
resist
potenti
cost
minim
use
narrow
spectrum
agent
reason
idsaat
consensu
guidelin
recommend
diagnost
test
microbi
caus
patient
sever
cap
includ
pretreat
blood
cultur
urinari
antigen
test
pneumonia
legionella
avail
sputum
cultur
expector
endotrach
bronchoscop
specimen
although
pretreat
cultur
optim
empir
therapi
significantli
defer
critic
ill
patient
purpos
specimen
acquisit
pretreat
blood
cultur
posit
icu
patient
cap
major
disadvantag
blood
cultur
acquisit
icu
patient
particular
vascular
cathet
situ
high
rate
fals
posit
due
skin
contamin
coagulaseneg
staphylococcu
high
expector
sputum
indic
unintub
patient
sever
cap
howev
result
must
interpret
context
specimen
qualiti
numer
strategi
propos
qualiti
evalu
institut
use
qualiti
score
denot
specimen
less
epitheli
cell
polymorphonuclear
pmn
cell
per
high
power
field
optim
specimen
epitheli
cell
discard
wherea
epitheli
cell
pmn
process
particular
histori
neutropenia
provid
specimen
recollect
advis
use
stat
sputum
gram
stain
help
detect
specif
pathogen
patient
sever
cap
empir
therapi
may
alter
base
gram
stain
morpholog
eg
gramposit
cocci
clumpsclust
suggest
aureu
local
preval
resist
profil
specif
pathogen
semiquantit
cultur
result
help
pathogen
present
least
microorgan
per
highpow
field
quantiti
sputum
cultur
result
must
interpret
caution
mani
respiratori
pathogen
colon
upper
andor
lower
respiratori
tract
addit
microorgan
caus
pulmonari
diseas
candida
speci
coagulaseneg
staphylococci
enterococci
commonli
isol
cultur
treat
respiratori
cultur
yield
substanti
higher
intub
versu
unintub
patient
endotrach
aspir
bronchoscop
sampl
obtain
sligl
marri
soon
possibl
follow
intub
interpret
may
improv
quantit
semiquantit
cultur
bronchoscopi
pursu
patient
suspect
pneumonia
specimen
obtain
nondiagnost
patient
immun
compromis
may
requir
bronchoscopi
less
common
difficult
identifi
pathogen
mycobacterium
tuberculosi
pneumocysti
jirovecii
fungi
bronchoscopi
may
also
use
purpos
exclud
diagnos
malign
diffus
alveolar
hemorrhag
hypersensit
pneumon
urinari
antigen
assay
avail
pneumonia
legionella
speci
advantag
urinari
antigen
test
critic
ill
patient
sever
cap
includ
high
sensit
specif
compar
sputum
gram
stain
cultur
rapid
turnaround
time
posit
even
initi
antibiot
major
disadvantag
urinari
antigen
test
lack
antibiot
suscept
data
compar
cultur
techniqu
addit
urinari
antigen
test
legionella
abl
detect
serogroup
howev
serogroup
account
approxim
legionella
infect
respiratori
viru
test
perform
patient
sever
cap
especi
influenza
season
multiplex
molecular
techniqu
becom
wide
avail
allow
simultan
test
multipl
respiratori
virus
rapid
turnaround
time
indic
icu
admiss
vari
among
patient
clinician
hospit
health
care
system
exampl
patient
comorbid
burden
sever
diseas
clinician
comfort
experi
well
avail
intermedi
care
within
institut
affect
icu
admiss
rate
cap
prompt
recognit
patient
sever
cap
essenti
optim
outcom
howev
previou
studi
shown
clinic
judgment
alon
accur
measur
pneumonia
sever
result
numer
prognost
score
system
develop
help
stratifi
patient
cap
sever
prognosi
mortal
well
aid
decis
site
care
outpati
ward
icu
beststudi
predict
rule
pneumonia
sever
index
psi
psi
deriv
unit
state
fine
colleagu
box
comprehens
score
made
demograph
physic
laboratori
find
stratifi
patient
class
accord
mortal
risk
design
identifi
lowrisk
patient
could
manag
ambulatori
set
psi
lack
abil
discrimin
among
sicker
patient
class
iv
v
patient
warrant
hospit
admiss
psi
help
stratif
need
icu
admiss
addit
psi
easili
underestim
sever
diseas
young
previous
healthi
patient
larg
number
point
alloc
age
comorbid
diseas
burden
box
develop
british
thorac
societi
somewhat
simpler
calcul
psi
use
pneumoniaspecif
criteria
score
one
sever
communityacquir
pneumonia
point
includ
acut
confus
blood
urea
nitrogen
level
greater
mmoll
respiratori
rate
greater
breathsmin
systol
blood
pressur
less
mm
hg
diastol
blood
pressur
less
equal
mm
hg
age
year
appear
discriminatori
compar
psi
neoplast
diseas
defin
cancer
except
basal
squamou
cell
cancer
skin
activ
time
present
diagnos
within
year
present
liver
diseas
defin
clinic
histolog
diagnosi
cirrhosi
anoth
form
chronic
liver
diseas
chronic
activ
hepat
congest
heart
failur
defin
systol
diastol
ventricular
dysfunct
document
histori
physic
examin
chest
radiograph
echocardiogram
multipleg
acquisit
scan
left
ventriculogram
cerebrovascular
diseas
defin
clinic
diagnosi
stroke
transient
ischem
attack
stroke
document
magnet
reson
imag
comput
tomographi
renal
diseas
defin
histori
chronic
renal
diseas
abnorm
blood
urea
nitrogen
creatinin
concentr
b
alter
mental
statu
defin
disorient
respect
person
place
time
known
chronic
stupor
coma
c
pneumonia
patient
outcom
research
team
cohort
studi
oxygen
satur
less
puls
oximetri
intub
admiss
also
consid
abnorm
among
patient
requir
hospit
admiss
score
greater
equal
denot
sever
diseas
may
warrant
icu
admiss
contrast
lack
comorbid
diseas
burden
make
easi
underestim
mortal
risk
elderli
frail
patient
may
decompens
significantli
even
mild
pneumonia
current
idsaat
guidelin
propos
set
criteria
suggest
patient
admit
icu
major
minor
criteria
see
box
major
criteria
includ
need
mechan
ventil
presenc
septic
shock
minor
criteria
includ
pao
fio
ratio
less
respiratori
rate
greater
breathsmin
multilobar
infiltr
systol
blood
pressur
less
mm
hg
despit
aggress
fluid
resuscit
blood
urea
nitrogen
level
greater
mgdl
leukopenia
cellsmm
thrombocytopenia
cellsmm
hypothermia
c
numer
valid
studi
support
use
criteria
recent
deriv
predict
rule
includ
smartcop
box
tool
aim
predict
need
intens
respiratori
vasopressor
support
irv
patient
cap
score
develop
cohort
patient
cap
requir
irv
maximum
point
accru
base
follow
criteria
systol
blood
pressur
less
mm
hg
multilobar
chest
radiograph
involv
albumin
less
gl
tachypnea
tachycardia
greater
beatsmin
acut
confus
low
oxygen
base
ageadjust
pao
spo
pao
fio
ratio
ph
less
author
defin
sever
cap
score
greater
equal
patient
receiv
irv
score
greater
equal
recent
metaanalysi
demonstr
similar
sensit
specif
idsaat
criteria
smartcop
outperform
psi
valid
howev
requir
predisposit
insult
respons
organ
dysfunct
piro
recent
develop
predict
mortal
specif
among
sever
cap
patient
requir
admiss
icu
box
maximum
score
variabl
includ
comorbid
copd
immun
compromis
age
greater
year
multilobar
diseas
shock
sever
hypoxemia
acut
renal
failur
bacteremia
ard
score
one
point
piro
score
perform
well
mortal
predict
tool
cap
patient
requir
icu
admiss
outperform
apach
ii
at
idsa
criteria
howev
valid
studi
requir
addit
criteria
suggest
sever
diseas
potenti
need
icu
admiss
includ
hypoglycemia
nondiabet
patient
lactat
greater
mmoll
na
less
meql
arteri
ph
less
cirrhosi
asplenia
addit
sever
hypoxia
need
highflow
oxygen
consid
decid
site
care
need
frequent
invas
clinic
andor
laboratori
monitor
patient
high
risk
decompens
may
also
warrant
icu
admiss
addit
pneumonia
predict
rule
discuss
numer
sever
score
avail
specif
assess
critic
ill
patient
popular
apach
ii
sap
ii
score
score
extens
use
also
well
valid
may
use
predict
mortal
critic
ill
patient
cap
score
also
serv
compar
critic
patient
across
unit
region
although
object
score
help
assess
sever
decid
site
care
alway
use
combin
physician
assess
empir
antimicrobi
therapi
initi
quickli
possibl
patient
sever
cap
guidelin
manag
cap
publish
variou
organ
notabl
idsaat
british
thorac
societi
local
adapt
guidelin
incorpor
local
epidemiolog
implement
whenev
possibl
empir
therapi
sever
cap
idsaat
guidelin
suggest
intraven
betalactam
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
macrolid
azithromycin
respiratori
fluoroquinolon
box
patient
signific
penicillin
allergi
respiratori
fluoroquinolon
aztreonam
recommend
although
patient
report
penicillin
allergi
studi
show
individu
fact
abl
toler
penicillin
addit
preval
immedi
immunoglobulin
emedi
penicillin
allergi
character
pruritu
flush
urticaria
angioedema
laryng
edema
andor
hypotens
appear
declin
crossreact
betalactam
use
penicillinallerg
patient
histor
overestim
recent
studi
suggest
thirdgener
cephalosporin
carbapenem
low
rate
crossreact
nonetheless
grade
challeng
may
appropri
patient
deem
high
risk
patient
risk
p
aeruginosa
treatment
includ
antipseudomon
betalactam
cefepim
imipenem
meropenem
piperacillintazobactam
plu
antipseudomon
fluoroquinolon
aminoglycosid
either
macrolid
azithromycin
respiratori
fluoroquinolon
ad
patient
treat
sever
communityacquir
pneumonia
betalactamaminoglycosid
combin
ensur
adequ
empir
atyp
coverag
aztreonam
substitut
betalactam
patient
seriou
penicillin
allergi
risk
camrsa
treatment
either
linezolid
vancomycin
initi
histor
vancomycin
drug
choic
patient
mrsa
cap
given
substanti
clinic
experi
howev
recent
random
clinic
trial
demonstr
improv
cure
rate
less
nephrotox
differ
mortal
use
linezolid
compar
vancomycin
mrsa
nosocomi
pneumonia
gener
result
patient
cap
howev
must
done
caution
addit
theoret
benefit
linezolid
treatment
camrsa
pneumonia
abil
decreas
toxin
product
would
particularli
desir
infect
due
pvlposit
camrsa
strain
linezolid
also
prefer
strain
higher
vancomycin
mic
term
mic
creep
clinic
failur
report
mic
greater
equal
mcgml
vancomycin
use
target
trough
level
optim
goal
mcgml
altern
agent
treatment
camrsa
infect
includ
telavancin
ceftarolin
clindamycin
trimethoprimsulfamethoxazol
may
also
use
patient
mild
diseas
suscept
isol
daptomycin
effect
treatment
pneumonia
inactiv
pulmonari
surfact
tigecyclin
use
extrem
caution
given
recent
warn
issu
us
food
drug
administr
regard
increas
mortal
associ
use
varieti
seriou
infect
announc
base
pool
analysi
clinic
trial
tigecyclin
given
approv
unapprov
indic
overal
risk
death
higher
patient
receiv
tigecyclin
versu
compar
antibiot
vs
rd
confid
interv
ci
although
differ
mortal
among
patient
cap
vs
rd
ci
use
tigecyclin
treatment
cap
discourag
empir
therapi
influenza
initi
neuraminidas
inhibitor
patient
compat
clinic
syndrom
influenza
season
critic
ill
patient
requir
invas
mechan
ventil
oseltamivir
prefer
zanamivir
inhal
powder
clog
ventil
tube
associ
advers
event
earli
initi
antivir
therapi
within
hour
symptom
onset
efficaci
howev
critic
ill
patient
suspect
influenza
treat
empir
regardless
time
symptom
onset
delay
antivir
therapi
although
benefici
earli
therapi
still
appear
improv
surviv
critic
ill
patient
antivir
therapi
also
shown
decreas
durat
viral
shed
treatment
discontinu
nucleic
acid
amplif
test
neg
continu
total
day
confirm
case
although
guidelin
recommend
highdos
oseltamivir
critic
ill
patient
pandem
recent
studi
demonstr
adequ
serum
level
standard
dose
droplet
contact
isol
use
prevent
nosocomi
transmiss
addit
airborn
precaut
recommend
aerosolgener
procedur
despit
lack
data
support
approach
combin
therapi
sever
cap
associ
improv
outcom
patient
bacterem
pneumococc
pneumonia
predominantli
sligl
marri
macrolidecontain
combin
regimen
despit
increas
macrolid
resist
treatment
efficaci
patient
pneumococc
cap
continu
demonstr
benefit
thought
due
immunomodul
macrolid
shown
downregul
leukocyt
adhes
inhibit
inflammatori
cytokin
product
therebi
decreas
inflammatori
respons
inde
macrolid
shown
improv
outcom
chronic
pulmonari
inflammatori
condit
asthma
copd
diffus
panbronchiol
bronchiectasi
recent
studi
demonstr
mortal
benefit
macrolidebas
treatment
acut
specif
treatment
sever
pneumonia
compar
nonmacrolidebas
therapi
furthermor
appear
impress
effect
exist
patient
sever
diseas
shock
presum
robust
system
inflammatori
respons
howev
mani
studi
observ
therefor
prone
confound
addit
greater
potenti
antimicrobi
toxic
need
consid
prescrib
combin
therapi
absenc
highlevel
evid
exampl
macrolid
long
associ
qtc
interv
prolong
recent
studi
demonstr
increas
risk
cardiovascular
death
patient
upper
respiratori
infect
receiv
azithromycin
baselin
cardiovascular
risk
factor
highest
risk
whether
critic
ill
patient
might
also
higher
risk
particular
given
concomit
use
qtc
prolong
medic
icu
known
studi
suggest
guidelin
concord
combin
therapi
target
typic
atyp
cap
pathogen
irrespect
specif
treatment
regimen
close
associ
improv
outcom
pathogendirect
therapi
pathogendirect
therapi
prescrib
etiolog
inform
becom
avail
narrowest
spectrum
agent
use
prevent
develop
antimicrobi
resist
effect
antimicrobi
therapi
administ
quickli
possibl
patient
sever
cap
variou
studi
demonstr
increas
mortal
critic
ill
patient
receiv
delay
antimicrobi
therapi
specif
critic
ill
patient
cap
administr
effect
antibiot
within
hour
admiss
compar
delay
therapi
associ
decreas
mortal
idsaat
guidelin
suggest
patient
admit
emerg
depart
ed
first
dose
antibiot
ideal
administ
still
ed
specif
time
threshold
specif
avoid
studi
suggest
less
hour
may
reason
goal
step
enter
therapi
switch
enter
antimicrobi
therapi
consid
patient
hemodynam
stabl
clinic
improv
ie
absenc
fever
hour
reduct
respiratori
symptom
numer
studi
cap
demonstr
safeti
approach
includ
patient
sever
psi
class
v
diseas
access
function
gastrointestin
tract
necessari
patient
remain
intub
requir
nasogastr
orogastr
tube
placement
specif
antimicrobi
bioavail
properti
need
care
consid
choos
optim
regimen
antimicrobi
excel
bioavail
includ
sever
communityacquir
pneumonia
fluoroquinolon
clindamycin
metronidazol
linezolid
trimethoprimsulfamethoxazol
gener
betalactam
poor
bioavail
antimicrobi
avail
intraven
formul
treatment
system
infect
aminoglycosid
vancomycin
nonrespons
common
patient
cap
occur
hospit
patient
approxim
icu
patient
mortal
rate
higher
nonrespond
compar
respond
lack
clear
definit
nonrespons
make
difficult
howev
compar
popul
fulli
understand
epidemiolog
nonrespons
idsaat
guidelin
propos
main
pattern
nonrespons
base
sever
studi
first
progress
pneumonia
clinic
deterior
acut
respiratori
failur
requir
ventilatori
support
andor
concomit
septic
shock
usual
within
hour
hospit
admiss
patient
initi
admit
hospit
ward
eventu
requir
icu
admiss
deterior
clinic
worsen
hour
like
relat
complic
parapneumon
effus
empyema
decompens
underli
comorbid
diseas
secondari
nosocomi
infect
second
patient
may
clinic
deterior
due
persist
nonrespond
pneumonia
defin
absenc
delay
achiev
clinic
stabil
risk
factor
nonrespons
includ
older
age
year
multilobar
pneumonia
greater
diseas
sever
liver
diseas
cavitari
diseas
parapneumon
effus
empyema
leukopenia
gramneg
infect
particular
resist
microorgan
legionella
pneumonia
guidelin
discord
antimicrobi
therapi
addit
possibl
inaccur
diagnosi
need
consid
patient
manag
nonrespond
patient
includ
diagnost
test
identifi
caus
pneumonia
determin
initi
present
rule
develop
resist
therapi
exclud
complic
empyema
nosocomi
superinfect
ct
scan
chest
thoracentesi
bronchoscopi
may
help
inadequ
host
respons
howev
common
caus
nonrespons
patient
treat
guidelin
concord
therapi
empir
antimicrobi
therapi
escal
may
appropri
diagnost
test
result
pend
patient
cap
receiv
day
antimicrobi
therapi
littl
data
guidelin
avail
critic
ill
patient
tradit
receiv
longer
cours
therapi
durat
therapi
depend
diseas
sever
antimicrobi
properti
halflif
bacteriostat
vs
bactericid
action
patient
immun
adequaci
clinic
respons
clinic
respons
observ
within
first
day
larg
metaanalysi
random
trial
patient
cap
found
differ
outcom
less
day
therapi
howev
two
trial
includ
hospit
patient
neither
includ
icu
patient
subsequ
cochran
review
examin
shortcours
day
versu
prolongedcours
day
therapi
hospitalacquir
pneumonia
critic
ill
patient
demonstr
reduc
ventilatorassoci
pneumonia
vap
recurr
due
multiresist
organ
increas
antibioticfre
day
differ
mortal
shortcours
therapi
howev
sligl
marri
recurr
vap
due
glucos
nonfer
gramneg
bacilli
greater
shortcours
therapi
base
data
would
suggest
similar
approach
patient
cap
therefor
longer
cours
therapi
consid
cap
due
glucos
nonferment
p
aeruginosa
acinetobact
baumannii
burkholderia
aureu
legionella
fungi
addit
patient
necrot
pneumonia
empyema
lung
abscess
extrapulmonari
infect
bacteremia
mening
endocard
requir
longer
cours
summari
treatment
durat
individu
base
patient
characterist
microbi
caus
clinic
respons
antimicrobi
stewardship
program
help
decreas
durat
narrow
spectrum
antimicrobi
therapi
pneumonia
common
caus
ard
patient
develop
ard
treat
lowvolum
openlung
ventil
strategi
patient
respond
convent
ventil
salvag
techniqu
includ
airwaypressur
releas
ventil
highfrequ
oscillatori
ventil
prone
posit
inhal
nitric
oxid
may
use
howev
none
strategi
shown
improv
surviv
patient
sever
sepsi
septic
shock
earli
goaldirect
therapi
resuscit
strategi
involv
goalori
manipul
cardiac
preload
afterload
contractil
achiev
balanc
system
oxygen
deliveri
oxygen
demand
shown
significantli
improv
outcom
addit
corticosteroid
supplement
administ
patient
vasopressordepend
shock
studi
demonstr
decreas
time
shock
revers
without
increas
advers
event
steroid
role
glucocorticoid
adjunct
therapi
sever
cap
absenc
septic
shock
well
defin
previou
studi
suggest
modest
mortal
benefit
sever
cap
other
unabl
reproduc
fact
demonstr
higher
rate
late
failur
given
pauciti
data
convinc
evid
suggest
use
adjunct
glucocorticoid
specif
sever
cap
absenc
septic
shock
time
extracorpor
membran
oxygen
ecmo
evalu
treatment
sever
respiratori
failur
ard
recent
publish
convent
ventilatori
support
versu
extracorpor
membran
oxygen
sever
acut
respiratori
failur
cesar
trial
random
patient
sever
respiratori
failur
pneumonia
ecmo
versu
convent
manag
sever
acut
respiratori
failur
defin
hypercapn
respiratori
acidosi
arteri
ph
less
sever
hypoxia
measur
murray
score
greater
point
allot
base
pao
fio
ratio
level
posit
endexpiratori
pressur
lung
complianc
chest
radiographi
patient
elderli
year
intub
longer
day
contraind
anticoagul
exclud
receiv
ecmo
significantli
lower
mortal
compar
control
vs
p
subsequ
cohort
studi
match
pair
ard
similarli
demonstr
lower
mortal
rate
vs
p
patient
receiv
ecmo
whether
ecmo
becom
avail
patient
sever
potenti
revers
acut
respiratori
failur
includ
cap
unrespons
convent
manag
remain
answer
patient
medic
center
ecmo
avail
author
advoc
therapi
select
patient
requir
transfer
ecmo
center
addit
risk
patient
transfer
need
care
consid
thromboembol
prophylaxi
stress
ulcer
prophylaxi
earli
enter
feed
use
critic
ill
patient
unless
contraind
assist
organ
support
provid
via
mechan
ventil
renal
replac
therapi
vasoact
medic
summar
comprehens
approach
treatment
patient
sever
cap
suggest
box
cigarett
smoke
lead
caus
prevent
mortal
result
death
per
year
unit
state
physician
address
smoke
statu
counsel
patient
regard
cessat
hospit
combin
behavior
support
pharmacolog
therapi
shown
increas
success
rate
vaccin
vaccin
provid
patient
admit
cap
prefer
hospit
discharg
immun
date
two
type
pneumococc
vaccin
avail
polysaccharid
conjug
prepar
vaccin
pneumococc
polysaccharid
vaccin
adult
shown
induc
elev
persist
function
antibodi
respons
box
sever
cap
bundl
care
approach
protect
invas
pneumococc
diseas
conjug
vaccin
develop
specif
improv
immunogen
children
polysaccharid
vaccin
recommend
adult
year
age
older
adult
less
year
age
longterm
care
facil
high
risk
invas
pneumococc
diseas
highrisk
condit
includ
chronic
alcohol
cigarett
smoke
homeless
asthma
inject
drug
use
chronic
cerebrospin
fluid
leak
chronic
neurolog
condit
presenc
cochlear
implant
chronic
cardiac
pulmonari
diseas
diabet
asplenia
sickl
cell
diseas
hemoglobinopathi
congenit
acquir
immunodefici
includ
transplant
patient
hiv
receiv
immunosuppress
therapi
chronic
kidney
liver
diseas
malign
neoplasm
singl
revaccin
recommend
year
first
dose
person
age
year
function
anatom
asplenia
person
immunocompromis
condit
addit
unit
state
advisori
committe
immun
practic
recommend
dual
vaccin
conjug
vaccin
adult
immunocompromis
condit
eg
hiv
infect
cancer
function
anatom
asplenia
solid
organ
transplant
cerebrospin
fluid
leak
cochlear
implant
chronic
renal
insuffici
nephrot
syndrom
patient
may
adequ
respons
polysaccharid
vaccin
ill
due
cap
either
isol
recurr
consid
indic
pneumococc
vaccin
howev
given
littl
downsid
author
suggest
routin
vaccin
patient
follow
cap
prefer
time
hospit
discharg
influenza
vaccin
administ
yearli
individu
month
age
older
although
highrisk
individu
close
contact
health
care
worker
priorit
infect
control
measur
includ
effect
hand
respiratori
hygien
well
appropri
isol
droplet
contract
airborn
depend
microorgan
help
prevent
spread
infect
hospit
addit
nosocomi
infect
prevent
strategi
hospitalassoci
ventilatorassoci
pneumonia
central
lineassoci
bloodstream
infect
catheterrel
urinari
tract
infect
practic
surgic
intervent
rare
requir
treatment
sever
cap
main
indic
surgic
intervent
achiev
sourc
control
set
empyema
lung
abscessnecrosi
empyema
drainag
achiev
via
tube
thoracostomi
larg
bore
chest
tube
requir
due
high
viscos
without
intrapleur
tissu
plasminogen
activ
administr
decort
may
requir
tube
thoracostomi
success
lung
abscess
necrot
pneumonia
thoracotomi
wedg
resect
occasion
requir
lastli
case
suspect
pneumonia
patient
unrespons
empir
therapi
bronchoscop
investig
nondiagnost
videoassist
thorac
surgeri
open
lung
biopsi
may
requir
diagnost
purpos
clinic
outcom
patient
sever
cap
includ
mortal
hospit
icu
longterm
eg
year
year
rate
hospit
icu
admiss
delay
sever
communityacquir
pneumonia
transfer
icu
treatment
failur
drug
toxic
advers
effect
therapi
antibiot
resist
hospit
icu
length
stay
readmiss
rate
unschedul
return
ed
primari
physician
offic
time
return
normal
daili
activ
patient
satisfact
cost
care
although
import
mortal
commonli
studi
outcom
undeni
hardest
endpoint
mortal
icu
patient
cap
higher
compar
patient
admit
hospit
ward
rang
variou
predictor
mortal
patient
sever
cap
includ
advanc
age
poor
function
statu
diseas
sever
multilobar
bilater
consolid
chest
radiograph
immun
compromis
presenc
renal
failur
need
mechan
ventil
hypotensionshock
nonadher
guidelin
multipl
organ
dysfunct
syndrom
mod
common
patient
sever
sepsi
septic
shock
demonstr
patient
admit
sever
cap
one
studi
organspecif
criteria
diagnosi
mod
includ
measur
pao
fio
ratio
serum
creatinin
platelet
count
glasgow
coma
score
serum
bilirubin
heart
rate
sequenti
organ
failur
assess
score
commonli
use
assess
incid
sever
organ
dysfunct
critic
ill
patient
develop
mod
correl
icu
hospit
mortal
common
pulmonari
complic
sever
cap
includ
empyema
lung
abscess
pneumothorax
ard
chronic
respiratori
failur
requir
tracheostomi
prolong
mechan
ventil
patient
requir
prolong
mechan
ventil
may
requir
specialti
pulmonari
ward
prolong
wean
surprisingli
high
mortal
rate
addit
major
cardiac
complic
acut
coronari
syndrom
congest
heart
failur
cardiac
arrhythmia
occur
consider
number
patient
cap
like
result
cardiac
stress
cellular
hypoxia
inflamm
critic
ill
cap
patient
cardiac
complic
particularli
high
risk
suffer
wors
outcom
compar
nonicu
cap
cohort
recognit
associ
may
improv
time
recognit
treatment
event
well
prevent
highrisk
popul
patient
delay
icu
admiss
ie
directli
admit
icu
transfer
hour
hospit
seem
higher
morbid
mortal
patient
cap
requir
icu
initi
admit
medic
ward
improv
abil
identifi
patient
time
hospit
admiss
prioriti
lastli
prognosi
also
shown
correl
microbi
caus
highest
mortal
gramneg
infect
nonrespons
therapi
hour
wors
outcom
vaccin
statu
larg
populationbas
cohort
studi
individu
previous
receiv
pneumococc
vaccin
lower
rate
mortal
icu
admiss
compar
vaccin
patient
cap
requir
icu
admiss
requir
mechan
ventil
present
concomit
septic
shock
typic
atyp
caus
microorgan
respons
cap
predict
base
patient
risk
factor
variou
score
system
psi
idsaat
criteria
avail
help
defin
cap
sever
prognosi
site
care
diagnosi
cap
critic
ill
patient
comprehens
includ
clinic
featur
plu
radiograph
laboratori
microbiolog
test
empir
antimicrobi
therapi
initi
quickli
possibl
adher
idsa
at
guidelin
wherev
possibl
target
antimicrobi
therapi
prescrib
microbi
caus
identifi
sourc
control
adjunct
therapi
assist
organ
support
includ
care
critic
ill
cap
patient
common
complic
suffer
patient
sever
cap
includ
empyema
lung
abscess
pneumothorax
ard
chronic
respiratori
failur
requir
tracheostomi
cardiac
complic
acut
coronari
syndrom
congest
heart
failur
arrhythmia
multisystem
organ
failur
prevent
strategi
need
emphas
